Brian K Law

List of Publications by Year
in descending order

69	2,272	201674	223800
papers	citations	27 h-index	46 g-index

76	76	76	4343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. Cancer Letters, 2022, 534, 215604.	7.2	4
2	Anticancer Agents Derived from Cyclic Thiosulfonates: Structureâ€Reactivity and Structureâ€Activity Relationships. ChemMedChem, 2022, 17, .	3.2	1
3	Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. IScience, 2022, 25, 104518.	4.1	3
4	Epithelialâ€“Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress. Cells, 2022, 11, 2208.	4.1	2
5	Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100053.	3.6	2
6	Cyclin-Dependent Kinases as Therapeutic Targets. , 2021, , 505-507.		0
7	Repurposing Tranexamic Acid as an Anticancer Agent. Frontiers in Pharmacology, 2021, 12, 792600.	3.5	4
8	A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica, 2019, 104, e415-e419.	3.5	48
9	Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discovery, 2019, 5, 153.	4.7	9
10	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. European Journal of Medicinal Chemistry, 2019, 161, 456-467.	5.5	13
11	A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene, 2019, 38, 4264-4282.	5.9	8
12	Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers. Aging Cell, 2018, 17, e12761.	6.7	60
13	The unfolded protein response as a target for anticancer therapeutics. Critical Reviews in Oncology/Hematology, 2018, 127, 66-79.	4.4	102
14	Abstract 447: A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. , 2018, , .		1
15	Grassystatins Dâ€“F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer. Journal of Natural Products, 2017, 80, 2969-2986.	3.0	31
16	Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer. Marine Drugs, 2017, 15, 290.	4.6	26
17	Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget, 2017, 8, 28971-28989.	1.8	11
18	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget, 2017, 8, 57246-57264.	1.8	13

#	Article	IF	Citations
19	Abstract 4050: Multifaceted targeting of drug-resistant EGFR+ and HER2+ breast tumors. , 2017, , .		0
20	CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Research, 2016, 18, 80.	5.0	25
21	Interaction between APC and Fen1 during breast carcinogenesis. DNA Repair, 2016, 41, 54-62.	2.8	16
22	Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. Journal of Clinical Investigation, 2016, 126, 4174-4186.	8.2	59
23	NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase Î² and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells. PLoS ONE, 2015, 10, e0123808.	2.5	28
24	VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFÎ²R signaling-dependent manner. Cancer Letters, 2015, 360, 60-67.	7.2	39
25	Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Molecular Pharmacology, 2015, 88, 846-852.	2.3	79
26	Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. Advances in Wound Care, 2015, 4, 321-328.	5.1	31
27	Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin. PLoS ONE, 2014, 9, e99927.	2.5	3
28	A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy, 2014, 10, 2021-2035.	9.1	190
29	The Basic Helixâ€Loopâ€Helix/Leucine Zipper Transcription Factor USF2 Integrates Serumâ€Induced PAIâ€1 Expression and Keratinocyte Growth. Journal of Cellular Biochemistry, 2014, 115, 1840-1847.	2.6	10
30	SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-â€œActivatedâ€• Keratinocytes. Advances in Wound Care, 2014, 3, 281-290.	5.1	67
31	CDCP1. , 2014, , 854-857.		0
32	Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development. Cancer Letters, 2013, 332, 120-129.	7.2	26
33	Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints. Journal of Cell Science, 2013, 126, 1207-1217.	2.0	17
34	Assembly, Activation, and Substrate Specificity of Cyclin D1/Cdk2 Complexes. Biochemistry, 2013, 52, 3489-3501.	2.5	18
35	The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin Association and Epithelial-to-mesenchymal Transition. Journal of Biological Chemistry, 2013, 288, 27680-27691.	3.4	42
36	Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents. Molecular Cancer Therapeutics, 2013, 12, 610-620.	4.1	88

#	Article	IF	Citations
37	Abstract 571: Overactive Cdk2 permits polyploidy by overwhelming the tetraploidy checkpoint.. , 2013, , .		0
38	Abstract PR16: A new class of small molecule acetyltransferase inhibitors discovered through high-throughput screening are potent anticancer agents with cancer-type specific activity. , 2013, , .		0
39	An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Letters, 2012, 326, 183-190.	7.2	26
40	In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in Bioscience - Landmark, 2011, 16, 803.	3.0	16
41	Î±B-Crystallin, an Effector of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells. Molecular Cancer Research, 2011, 9, 1632-1643.	3.4	59
42	Abstract 2951: Regulation of E2F-dependent transcription by the mTORC1 pathway. , 2011, , .		0
43	Abstract 2943: Targeting the E2F pathway in cancer chemotherapeutics. , 2011, , .		0
44	Abstract 2895: The epithelial to mesenchymal transition is associated with alterations in the mitogenic signaling pathways that drive cancer cell proliferation. , 2011, , .		0
45	Abstract 3923: Constitutive Cdk2 activation results in endoreduplication, failed cytokinesis, and chromosomal instability. , 2011, , .		0
46	Abstract A71: Cdk2, Mad2, and the tetraploidy checkpoint in paclitaxel-induced endoreduplication.. , 2011, , .		0
47	The B56Î³3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition. Journal of Biological Chemistry, 2010, 285, 21567-21580.	3.4	35
48	Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-ÎºB using in silico molecular docking. Cancer Letters, 2010, 291, 217-224.	7.2	18
49	Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 351-361.	2.5	106
50	Abstract 3881: A novel class of structure-based cyclin-dependent kinase inhibitors. , 2010, , .		0
51	Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation. Molecular Pharmacology, 2009, 76, 91-104.	2.3	129
52	A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism. Journal of Biological Chemistry, 2009, 284, 29945-29955.	3.4	18
53	Amino Acid Asp181 of 5â€²-Flap Endonuclease 1 Is a Useful Target for Chemotherapeutic Development. Biochemistry, 2009, 48, 9952-9958.	2.5	34
54	Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest. Differentiation, 2009, 78, 35-44.	1.9	28

#	Article	IF	Citations
55	Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-Î°B. Cancer Letters, 2009, 275, 139-149.	7.2	18
56	Novel Cdk inhibitors identified by in silico screening act through a novel mechanism. FASEB Journal, 2009, 23, 756.17.	0.5	0
57	Abstract A17: Transforming growth factor beta stimulates STAT3 tyrosine phosphorylation and cellular invasion through interleukinâ€6 in human breast cancer cell lines. , 2009, , .		0
58	Identification of novel Smad2 and Smad3 associated proteins in response to TGFâ€Î²1. Journal of Cellular Biochemistry, 2008, 105, 596-611.	2.6	49
59	Mammary Tumors Initiated by Constitutive Cdk2 Activation Contain an Invasive Basal-like Component. Neoplasia, 2008, 10, 1240-1252.	5.3	27
60	Lessons From the First Comprehensive Molecular Characterization of Cell Cycle Control in Rodent Insulinoma Cell Lines. Diabetes, 2008, 57, 3056-3068.	0.6	52
61	Tumors Initiated by Constitutive Cdk2 Activation Exhibit Transforming Growth Factor Î² Resistance and Acquire Paracrine Mitogenic Stimulation during Progression. Cancer Research, 2007, 67, 3135-3144.	0.9	22
62	Transforming Growth Factor-Î² and Cancer. , 2007, , 91-111.		1
63	Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes. Cancer Research, 2006, 66, 1070-1080.	0.9	63
64	Rapamycin: An anti-cancer immunosuppressant?. Critical Reviews in Oncology/Hematology, 2005, 56, 47-60.	4.4	223
65	Construction of a Cyclin D1-Cdk2 Fusion Protein to Model the Biological Functions of Cyclin D1-Cdk2 Complexes. Journal of Biological Chemistry, 2004, 279, 47688-47698.	3.4	49
66	Rapamycin Potentiates Transforming Growth Factor Î²-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer Cells. Molecular and Cellular Biology, 2002, 22, 8184-8198.	2.3	102
67	Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen. Journal of Biological Chemistry, 2000, 275, 38261-38267.	3.4	75
68	Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple Stimuli. Journal of Biological Chemistry, 2000, 275, 10796-10801.	3.4	42
69	Sensitization of FOLFOX-Resistant Colorectal Cancer Cells via the Modulation of a Novel Pathway Involving Protein Phosphatase 2A. SSRN Electronic Journal, 0, , .	0.4	0